Welcome to our dedicated page for Interpace Biosciences news (Ticker: IDXG), a resource for investors and traders seeking the latest updates and insights on Interpace Biosciences stock.
Interpace Biosciences, Inc. reports news centered on molecular diagnostic testing through Interpace Diagnostics, with a current focus on thyroid cancer risk assessment. The company’s commercial thyroid offering pairs ThyGeNEXT, a next-generation sequencing assay for thyroid nodules, with ThyraMIRv2, a proprietary microRNA expression profiler and algorithmic classifier.
Recurring updates cover thyroid test volume, revenue, cash collections, reimbursement developments, scientific presentations and business results. Company news also includes capital-structure actions such as repayment of outstanding debt, conversion of preferred stock into common stock, and the completed discontinuation of PancraGEN as Interpace shifted to a thyroid-focused diagnostics model.
Interpace Biosciences (OTCID: IDXG) will implement a 1-for-5 reverse stock split of its issued and outstanding common stock, effective 12:01 a.m. ET on August 27, 2026. Trading on a split-adjusted basis on OTCID is expected to begin at market open that day under temporary ticker IDXGD for 20 trading days, with new CUSIP 46062X402.
According to Interpace, outstanding common shares will decrease from approximately 27.7 million to approximately 5.5 million, while authorized shares and par value remain unchanged. The split, approved by stockholders and the Board on August 20, 2026, is primarily intended to help satisfy Nasdaq Capital Market minimum bid price requirements for a potential uplisting, although Nasdaq listing is not guaranteed.
Interpace Biosciences (OTCQX: IDXG) reported Q2 2026 revenue of $9.1 million, down 1% from reported Q2 2025 but up 9% versus Pro Forma thyroid-only revenue of $8.4 million. Income from continuing operations was $0.3 million (3% margin), versus a $0.5 million loss a year ago, and included approximately $0.2 million of non-recurring professional fees.
Q2 gross margin rose to 62% from 54% on a Pro Forma basis and Adjusted EBITDA increased to $0.7 million (8% margin) from $0.2 million (3% margin) Pro Forma. Trailing twelve‑month thyroid revenue reached $36.1 million, up about 11% Pro Forma on 10% volume growth. Operational KPIs improved, including 3% higher thyroid revenue per test, 17% faster turnaround time, and 5% more accounts. The company remains debt-free, is adding a Chief Scientific Officer in September 2026, and is advancing a pancreatic cancer diagnostics program that is not expected to generate revenue in 2026.
Interpace Biosciences (OTCQX: IDXG) reported Q1 2026 revenue of $9.0 million, income from continuing operations of $0.8 million, and Adjusted EBITDA of $1.6 million (17% margin). Thyroid revenue grew 12% year-over-year on 10% higher volume, with gross margin rising to 65% from 59% Pro Forma. Management reaffirmed 2026 guidance for about 16% thyroid revenue growth and highlighted improvements in average revenue per test, DSO, turnaround time, account volume, and a debt-free balance sheet.
Interpace Biosciences (OTCQX: IDXG) reported Q4 2025 revenue of $9.2M and full-year 2025 revenue of $38.7M. Income from continuing operations was $22.8M in Q4 and $25.0M for 2025, driven by a one-time, non-cash deferred tax valuation allowance release. Thyroid revenue rose 14% in Q4 and 21% for FY, with thyroid test volume up 11% in Q4 and 13% for FY. The company paid off debt in Q4, increased cash availability by $4.3M year-over-year, and reported operational improvements including a 19% DSO reduction and 20% faster turnaround time.
Interpace Biosciences (OTCID: IDXG) reported preliminary unaudited 2025 revenue of approximately $38–39 million, with $34–35 million from thyroid testing, a ~21% increase versus 2024. The company initiated full-year 2026 revenue guidance of ~$40 million, implying ~16% thyroid revenue growth versus 2025. All Series C preferred shares converted into common stock, resulting in issuance of ~23,267,327 common shares and a pro forma share count of ~27.7 million. Management reports the company is debt-free after paying off 100% of outstanding debt in December and intends to seek a Nasdaq uplisting in 2026, although no assurance of success is given.
Interpace Biosciences (OTCID: IDXG) announced on December 3, 2025 that it has fully repaid its outstanding term loan facility with BroadOak Capital Partners prior to the facility's maturity date. The repayment satisfies obligations under the Loan and Security Agreement originally entered on October 29, 2021. By retiring the debt early, the company said it eliminates related interest expenses, increases operational flexibility, and strengthens its balance sheet to support future commercial growth. Management framed the move as part of a strategic turnaround to profitability and said the company continues to deliver record testing volumes and revenue for its thyroid tests.
Interpace Biosciences (OTCQX: IDXG) reported third quarter 2025 results for the period ended September 30, 2025. Net revenue was $8.8 million; cash collections were $10.0 million. The company said thyroid test volume rose 12% year‑over‑year and thyroid revenue reached a record $8.8M, up 22% versus a prior pro forma quarter, while average revenue per test increased 5%. Management reported income from continuing operations of $1.0 million and adjusted EBITDA of $1.3 million. The company noted a 22% reduction in days sales outstanding and additional principal payments on long‑term debt tied to stronger cash flow.
Interpace Biosciences (OTCQX: IDXG) presented two significant scientific posters at the 2025 American Thyroid Association Annual Meeting in Scottsdale, Arizona. The first poster demonstrated that their testing platform successfully yielded molecular results in 86% (56 out of 65) of thyroid FNA cases previously deemed insufficient by another platform, using archival cytology slides.
The second poster analyzed 28,144 indeterminate thyroid nodules, showing that ThyGeNEXT identified BRAF V600E-like alterations in 4-6% and RAS-like alterations in ~19% of cases, while 76-77% were mutation-negative. The ThyraMIRv2 microRNA profiling further refined malignancy risk assessment, with over 90% of mutation-negative nodules classified as low risk.
Interpace Biosciences (OTCQX:IDXG) reported mixed Q2 2025 financial results, with net revenue of $9.2 million, down 23% year-over-year. Despite overall revenue decline, the company achieved record thyroid testing performance, with volume up 16% and revenue up 25% year-over-year to $8.7 million.
The company reported a Q2 loss from continuing operations of $0.5 million, compared to income of $2.5 million in Q2 2024, primarily impacted by $1.2 million in one-time charges related to PancraGEN testing discontinuation. Cash collections remained strong at $10.8 million, and preliminary July 2025 revenue showed a 54% year-over-year increase to $3.3 million.
Interpace is transitioning to focus exclusively on thyroid testing, following the loss of PancraGEN reimbursement. The company maintains a positive outlook for Q3 2025 and beyond as a thyroid-only diagnostics business.
Interpace Biosciences (OTCQX: IDXG) reported strong financial results for Q1 2025, with revenue reaching $11.5 million, a 13% increase year-over-year. The company achieved record thyroid test revenue of $8.0M (up 19%) and record thyroid test volume (up 16%). Cash collections hit record levels at $11.3 million, up 10% from the previous year.
Key financial metrics showed significant improvement, with gross profit margin increasing to 64% from 62%, and income from continuing operations reaching $1.8 million, a $0.9 million improvement over Q1 2024. The company initiated full-year 2025 revenue guidance of approximately $38 million, despite the anticipated loss of PancraGEN revenue after May 2, 2025.